We, therefore, tested a novel noninvasive cervical transcutaneous VNS approach in a mouse model of intracranial aneurysm formation and rupture that recapitulates the clinical features as well as the inflammatory mechanisms. 5, [12] [13] [14] We examined clinically relevant acute outcome end points including rupture rate and survival after rupture using 2 different levels of model severity. Data strongly suggest that chronic daily VNS inhibits aneurysm rupture and implicate reduced MMP-9 (matrix metalloproteinase-9) expression as one mechanism. Postrupture survival is also improved by VNS regardless of the degree of SAH.
Methods
Experiments were conducted in accordance with the Guide for Care and Use of Laboratory Animals (NIH Publication No. 1996) and approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee. Experimental protocol and timeline are summarized in Figure 1A . See the online-only Data Supplement for the preclinical checklist required by the journal.
Intracranial Aneurysm Model
Intracranial aneurysms were induced using intracranial elastase injection combined with systemic deoxycorticosterone acetate-salt hypertension in mice (8-to 10-week-old, male, C57BL/6; Charles River Laboratories, Wilmington, MA), as described previously with minor modifications ( Figure 1A) . 5, 12 All mice underwent unilateral nephrectomy. One week later, a deoxycorticosterone acetate pellet (66 mg, 28-day release; Innovative Research of America, Sarasota, FL) was implanted, and 1% NaCl was added to drinking water to induce systemic hypertension. A single dose of elastase (35 mU; E7885, porcine pancreatic elastase, lyophilized powder, 20 mg; Sigma Aldrich, StLouis, MO) was stereotaxically injected into the right basal cistern (2.6 mm posterior, 1.5 mm lateral, and 5.7 mm ventral to bregma) after a midline scalp incision under isoflurane anesthesia (3% induction, 1% maintenance, in 30% O 2 and 70% N 2 O). A separate cohort of mice (severe model) additionally received high-salt diet (0.39% NaCl) and supplemental doses of deoxycorticosterone acetate powder (34 mg every other day subcutaneously, in 0.1 mL olive oil) for higher mean arterial pressures ( Figure 1B ) and worse outcomes.
In the mild model, blood pressures (BPs) were measured via a femoral artery catheter under general anesthesia (isoflurane 2.5% induction, 1% maintenance in 70% N 2 O and 30% O 2 ) at the time of euthanasia. In the severe model, mortality and morbidity were high and significantly differed between VNS and femoral nerve stimulation (FNS) groups, precluding measurements just before euthanasia. Therefore, in the severe model, we measured the BPs using the same method, but on day 5 in a separate dedicated cohort that has undergone identical procedures.
Vagus or Femoral Nerve Stimulation
The day after elastase injection, animals were randomly assigned to either right transcutaneous (cervical) VNS or transcutaneous (inguinal) FNS groups. We selected FNS because we aimed (1) to control for any potential effects of cutaneous stimulation and muscle twitching, (2) to avoid an autonomic nerve that may have effects of its own, and (3) to stay away from the cervical region to avoid inadvertent vagus stimulation in this small species. The stimulus consisted of 1-ms pulses of 5-kHz sine waves, repeated at 25 Hz, for 2 minutes, delivered twice 5 minutes apart ( Figure 1A ) using custom-made bipolar stimulation electrodes connected to the gammaCore device (electroCore, Basking Ridge, NJ). For each transcutaneous stimulation session, we titrated the stimulus intensity to be just above the muscle twitch threshold (≈7-9 V), similar to that used in patients. This noninvasive VNS protocol has previously been shown to successfully activate the vagus nerve [15] [16] [17] [18] and has been efficacious in other animal models such as focal cerebral ischemia, pain, and spreading depression. [19] [20] [21] [22] [23] Stimulation was delivered once daily until euthanasia by placing the electrodes on the shaved skin on the right side under brief general anesthesia. In a separate cohort, we detected only a 12±3% decrease in BP and a 19±7% decrease in HR during VNS, both of which started to recover even before the end of the 2-minute stimulation and completely resolved within 3 minutes. These mild and brief hemodynamic effects of VNS were unlikely to alter the course of aneurysm formation and rupture. More important for the latter, resting state BPs did not differ between VNS and FNS groups ( Figure 1B ).
Outcome Measures
Two observers, one of whom was blinded to the treatment arm, performed neurological examinations daily. Neurological signs were graded as follows: 0, normal function; 1, reduced activity or weight loss >2 g of body weight (≈10% weight loss) for 24 hours; 2, flexion of the torso and forelimbs on lifting the animal by the tail; 3, circling to one side with normal posture at rest; 4, leaning to one side at rest; 5, no spontaneous activity; and 6, sudden spontaneous death. When mice developed severe signs (grades 4 or 5), they were euthanized. Because previous studies using this model showed that aneurysmal rupture occurs within 3 weeks of aneurysm induction, all remaining mice were euthanized 21 days after aneurysm induction. Before euthanasia, mean arterial pressures were measured via a femoral artery catheter under isoflurane anesthesia. After euthanasia, mice were transcardially perfused with 5 mL heparinized saline followed by 0.5 mL carbon black ink (0.1 mL/s). Brains were carefully removed to preserve the integrity of the circle of Willis and ventral surface imaged under a stereomicroscope for morphological changes. Majority of animals developed some degree of dolichoectasia and tortuosity ( Figure 1C ) with increased diameters of the circle of Willis arteries; the latter was measured using a scale in view ( Figure 1C ). Aneurysms were defined as localized outward bulging of the vascular wall, with the largest diameter greater than that of the parent artery. Aneurysms were often not filled with the dye indicating some degree of thrombosis. The number of aneurysms and the largest diameter of each aneurysm were quantified in each animal. SAH severity was graded as follows: 0, no hemorrhage; 1, localized hemorrhage, thin SAH; 2, multiple or broad hemorrhage, diffuse thick SAH; and 3, massive hemorrhage ( Figure 1D ). In a separate cohort, we studied proinflammatory marker expression within the circle of Willis in a blinded fashion (n=6 each, VNS and FNS). Four days after the induction of aneurysms using the severe model as described above, we performed transcardiac saline perfusion and harvested the circle of Willis arteries. We measured mRNA expression of TNF-α (tumor necrosis factor-α), IL-1β (interleukin-1β), , iNOS (inducible nitric oxide synthase), MMP-9, and CCL2 (chemokine C-C motif ligand 2; also known as MCP-1 [monocyte chemotactic protein-1]), using reverse transcriptase polymerase chain reaction. Tissues were frozen in liquid nitrogen and kept in −80°C freezer until RNA extraction. RNA was extracted using a commercial RNA extraction kit (Zymo Research, Irvine, CA) and converted to cDNA using a SuperScript III FirstStrand Synthesis System kit (Invitrogen, Carlsbad, CA) according to manufacturer's instructions. Reverse transcriptase polymerase chain reaction was performed using TaqMan Gene Expression Assays and TaqMan Fast Advanced Master Mix (Applied Biosystems, Foster City, CA) with the following inflammatory marker primers: MMP-9, IL-1β, TNF-α, CCL2, IL-6, iNOS, and the housekeeping gene 18S. All primers were purchased from Applied Biosystems. Reverse transcriptase polymerase chain reaction was performed in a 7500 Fast Real-Time PCR system (Applied Biosystems, Foster City, CA) in triplicates. Relative mRNA expression levels were normalized to housekeeping gene.
Primary outcome end points were survival, deficit-free survival, deficit grade, rupture rate, and SAH grade. Secondary outcome end points were the presence or absence of tortuosity, circle of Willis artery diameters, and aneurysm counts, sizes and distribution. Proinflammatory marker mRNA expression was an exploratory end point. Sample sizes were chosen empirically (n=16/group for the mild model and n=14/group for the severe model) in the absence of prior experience with elastase technique in our lab. Mice were excluded
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if they failed to attain a target arterial BP of at least 95 mm Hg by induced-hypertension paradigm (n=6 FNS, 2 VNS in mild model), if they developed severe neurological deficits (grade 4-5) but without evidence of elastase effect on subsequent morphological examination (no tortuosity in any vessel, SAH, or aneurysm) suggesting unrelated cause (n=1 FNS and 1 VNS), and technical failure during elastase injection (n=3, before being assigned to a treatment arm). Only one animal was excluded in FNS group in gene expression experiment because of complete absence of tortuosity in any of the circle of Willis arteries, suggesting lack of elastase effect.
Statistical Analysis
All results were expressed as whisker-box plots (whiskers, full range; box, interquartile range; horizontal line, median; +, mean), mean±SEM, or as median (95% CI). Statistical testing was performed using Prism 6 (GraphPad Software, San Diego, CA). Individual statistical tests for each dataset are indicated in Figure or 
Results
The elastase plus induced-hypertension model led to aneurysm formation and spontaneous ruptures with various severities of SAH and neurological deficits. In the milder model, most animals survived the 21-day follow-up period ( Figure 2A , upper left), although some developed neurological deficits during the follow-up (Figure 2A , lower left). Deficit-free survival tended to be higher (P=0.055; Figure 2A , lower left) and neurological deficit grades milder (P=0.095; Figure 2B , left) in the VNS group compared with the FNS (n=14 and 10, respectively). Maximum body weight loss did not differ between FNS and VNS groups in the mild model (6.1±0.9% versus 6.4±0.5%, respectively; unpaired t test). Postmortem examinations revealed gross morphological evidence for SAH, indicating aneurysmal rupture in 80% of animals in the FNS group ( Figure 2C , upper left). VNS significantly reduced rupture rates (29%; P=0.036).
The relative risk of rupture was more than 3-fold higher in the FNS group compared with VNS (relative risk=3.6, CI [1.0-12.9]). SAH grades were also significantly lower in the VNS group (P=0.025; Figure 2C , lower left). In contrast, aneurysm counts ( Figure 3A , upper left) did not differ between the groups. Although aneurysm diameters were statistically smaller in the VNS group ( Figure 3A , lower left), the magnitude of this effect was of uncertain biological significance. Figure 3B , left). However, aneurysms developed farther from the injection site in FNS group compared with VNS ( Figure 3C , left). The severe model resulted in much higher mortality (P<0.001) and lower deficit-free survival rates (P<0.001) compared with the milder model in FNS controls (Gehan-Breslow-Wilcoxon test; Figure 2A , left versus right). In the severe model, compared with FNS, VNS significantly improved survival (median survival 13 versus 6 days, respectively, n=13 each; P=0.003) and deficit-free survival rates (median deficit-free survival 6 versus 4 days, respectively, P=0.029), without affecting neurological deficit grades ( Figure 2B, right) , rupture rates, or SAH grades ( Figure 2C, upper and lower right) . Maximum body weight loss was similar between FNS and VNS groups (11.2±1.8% versus 10.2±1.3%, respectively; unpaired t test). Aneurysm counts or sizes ( Figure 3A, upper Figure 3B , right) nor the average distance of aneurysms from the injection site differed between the FNS and VNS groups ( Figure 3C , right). Arterial diameters and presence of tortuosity in the circle of Willis also did not differ between FNS and VNS groups in either the mild or the severe model (Table) , suggesting that VNS did not directly interfere with elastase effect.
After finding reduced rupture rates and improved survival after rupture in the VNS group, we also explored whether the anti-inflammatory effects of VNS may play a role. To this end, we measured the expression of proinflammatory mediators within the circle of Willis 7 days after elastase injection in the severe model. Expression was low in naïve circle of Willis (not shown). VNS generally suppressed the expression of all proinflammatory mediators compared with FNS (−34% MMP-9, −21% IL-1β, −44% TNF-α, −25% CCL2, −28% IL-6, and −12% iNOS), although this effect reached statistical significance only for MMP-9 in this exploratory cohort (n=5 and 6, FNS and VNS, respectively; Figure 4) . Importantly, SAH grades in this cohort were mild and comparable between the groups (FNS, 1.20±0.20 and VNS, 1.00±0.26), suggesting that VNS suppressed the inflammatory response rather than SAH severity.
Discussion
Our data in an experimental intracranial aneurysm model with 2 levels of severity show that VNS reduces rupture rate in the mild version and improves postrupture survival and neurological deficits in the more severe version. We used 2 different model severities because neither alone allowed us to test all intended end points. Survival was nearly 100% in the mild model; therefore, mild model did not allow us to assess VNS effect on survival. Conversely, nearly all animals developed a ruptured aneurysm in the severe model; therefore, severe model did not allow us to assess rupture rates. Together, the 2 variations of the model complemented each other and independently yielded outcomes consistently favoring VNS.
Given the role of inflammation in aneurysm formation and growth, [1] [2] [3] [4] [5] and the well-known anti-inflammatory effects of VNS, 8, 9 suppression of inflammation is likely to be the mechanism of VNS action in this model. This is also supported by our exploratory data showing a significant Whitney test) . C, Rupture rates (upper row) and SAH grades (lower row) are shown for mild (left) and severe (right) models. Rupture rates were compared between FNS and VNS using Fisher exact test and subarachnoid hemorrhage (SAH) grades using Mann-Whitney U test.
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reduction in MMP-9 and an overall trend for reduced expression of proinflammatory markers within the circle of Willis arteries. MMP-9, the main gelatinase produced by macrophages, is associated with cerebral aneurysm rupture and may predict poor prognosis. 5, 8, 24 MMP-9 also plays a critical role in outward vascular remodeling in a mouse common carotid artery ligation model. 25 VNS has been shown to reduce MMP-9 expression in macrophages 9, 26 and prevent abdominal aortic aneurysm formation by suppressing inflammatory cytokines and MMP activity. 27 Interestingly, VNS has reduced the expression of MMP-9 in models of postmyocardial infarction remodeling and cardiac dysfunction as well. 28 Although statistically not significant in our exploratory studies, suppression of other cytokines by VNS may also contribute. For example, TNF-α has been shown to play a critical role in aneurysm formation and rupture, 4, 29 and a reduction in CCL2 may suppress aneurysm growth and rupture by limiting macrophage infiltration. Of note, gammaCore device that we used selectively stimulates the low-threshold, myelinated, Aβ afferents to the brain stem, rather than the high-threshold, nonmyelinated, efferent C fibers. Vagal afferents project to nucleus tractus solitarius and from there to numerous subcortical neuromodulatory nuclei, including basal forebrain and locus ceruleus. Therefore, central mechanisms of VNS action may also play a role in this model. Clearly, more studies are needed to elucidate the mechanisms of action of VNS on aneurysm growth and rupture and to dissect its molecular mediators.
Improved survival and deficits in the severe model despite comparable rupture rates and SAH grades strongly suggest that VNS has a protective effect on brain tissue as well. In massive ruptures, brain tissue suffers variable degrees of global ischemia because of a rise in intracranial pressure, as well as focal ischemia due to potential interruption of blood flow downstream to the ruptured vessel. VNS has uniformly improved outcomes in animal models of ischemic stroke, 19, 23, 28, 30 and anti-inflammatory mechanisms have been implicated as one mechanism. 23, 26 Therefore, it is possible that in addition to preventing aneurysm growth and rupture, VNS may improve outcome after SAH.
Although the elastase-hypertension model of intracranial aneurysms we used here is among the most widely used experimental models to examine aneurysm development and rupture, 5, 6, 12, [31] [32] [33] it does have caveats. One such caveat is the unpredictable timing of rupture and survival and deficits after a rupture. For example, sudden death because of massive SAH precludes ink perfusion for anatomic examination for aneurysms. Moreover, after massive SAH, ruptured aneurysms may clot or collapse, making them harder to identify. Therefore, it is likely that some aneurysms were undetected, 
which might explain the lack of differences in aneurysm counts or diameters between mild or severe models or between FNS and VNS groups. No doubt these data will have to be independently confirmed, preferably in more than one model, sex and species, and incorporating longer-term outcomes. However, given the outstanding safety and tolerability profile of noninvasive VNS, and easy bedside or ambulatory implementation, there is ample opportunity for rapid translation of these findings into clinical use. For example, chronic daily VNS can be used prophylactically to prevent aneurysm formation in patients with known propensity (eg, fibromuscular dysplasia) or growth in patients with known unruptured aneurysms. Management of such patients is currently limited to follow-up neuroimaging only. In addition, VNS can also be used after rupture to improve SAH outcomes, which would be easy to implement at the bedside. Of course, more work is needed to determine the optimal therapeutic paradigms for these applications. 
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